tetano
Editor, Senior Moderator
Curr Hypertens Rep
. 2022 Jun 15.
doi: 10.1007/s11906-022-01195-4. Online ahead of print.
Preeclampsia and COVID-19: the Role of Inflammasome Activation
Denise C Cornelius[SUP] 1 [/SUP], Xi Wang[SUP] 2 [/SUP], Ashley Griffin[SUP] 3 [/SUP], Rachael Morris[SUP] 4 [/SUP], Kedra Wallace[SUP] 5 6 7 [/SUP]
Affiliations
Abstract
Purpose of review: It is well established that controlled immune activation and balance is critical for women's reproductive health and successful pregnancy outcomes. Research in recent decades in both clinical and animal studies has demonstrated that aberrant immune activation and inflammation play a role in the development and progression of women's reproductive health and pregnancy-related disorders. Inflammasomes are multi-protein cytoplasmic complexes that mediate immune activation. In this review, we summarize current knowledge on the role of inflammasome activation in pregnancy-related disorders.
Recent findings: Increased activation of inflammasome is associated with multiple women's health reproductive disorders and pregnancy-associated disorders, including preeclampsia (PreE). Inflammasome activation is also associated with the novel coronavirus disease 2019 (COVID-19) disease caused by the SARS-Cov-2 virus. We and others have observed a positive association between increased PreE incidences with the onset of the COVID-19 pandemic. Here, we present our recent data indicating increased inflammasome activation, represented by caspase-1 activity, in women with COVID-19 and PreE compared to normotensive pregnant women COVID-19. The role of inflammation in pregnancy-related disorders is an area of intense research interest. With the onset of the COVID-19 pandemic and the associated increase in PreE observed clinically, there is a greater need to identify mechanisms of pathophysiology and targets to treat this maternal disorder. Inflammasome activation is associated with PreE and COVID-19 infection and may hold therapeutic potential to improve outcomes associated with PreE and curb the morbidity attributed to PreE.
Keywords: COVID-19; Inflammasome; NLRP3; Preeclampsia.
. 2022 Jun 15.
doi: 10.1007/s11906-022-01195-4. Online ahead of print.
Preeclampsia and COVID-19: the Role of Inflammasome Activation
Denise C Cornelius[SUP] 1 [/SUP], Xi Wang[SUP] 2 [/SUP], Ashley Griffin[SUP] 3 [/SUP], Rachael Morris[SUP] 4 [/SUP], Kedra Wallace[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 35704142
- DOI: 10.1007/s11906-022-01195-4
Abstract
Purpose of review: It is well established that controlled immune activation and balance is critical for women's reproductive health and successful pregnancy outcomes. Research in recent decades in both clinical and animal studies has demonstrated that aberrant immune activation and inflammation play a role in the development and progression of women's reproductive health and pregnancy-related disorders. Inflammasomes are multi-protein cytoplasmic complexes that mediate immune activation. In this review, we summarize current knowledge on the role of inflammasome activation in pregnancy-related disorders.
Recent findings: Increased activation of inflammasome is associated with multiple women's health reproductive disorders and pregnancy-associated disorders, including preeclampsia (PreE). Inflammasome activation is also associated with the novel coronavirus disease 2019 (COVID-19) disease caused by the SARS-Cov-2 virus. We and others have observed a positive association between increased PreE incidences with the onset of the COVID-19 pandemic. Here, we present our recent data indicating increased inflammasome activation, represented by caspase-1 activity, in women with COVID-19 and PreE compared to normotensive pregnant women COVID-19. The role of inflammation in pregnancy-related disorders is an area of intense research interest. With the onset of the COVID-19 pandemic and the associated increase in PreE observed clinically, there is a greater need to identify mechanisms of pathophysiology and targets to treat this maternal disorder. Inflammasome activation is associated with PreE and COVID-19 infection and may hold therapeutic potential to improve outcomes associated with PreE and curb the morbidity attributed to PreE.
Keywords: COVID-19; Inflammasome; NLRP3; Preeclampsia.